Curanex Pharmaceuticals Inc: two securities class actions filed

What happened

• Curanex Pharmaceuticals Inc reported on Oct 19, 2026 that plaintiffs filed two putative securities class actions in the Supreme Court of the State of New York, New York County. On Jul 23, 2026 Daymond Morales, et al., filed Action 1 (Index No. 159271/2026) against the Company, underwriters Dominari Securities LLC, Pacific Century Securities, LLC, Revere Securities LLC, and more than 20 other issuers, underwriters, and individual principals. On Sep 14, 2026 Robert Lovett filed Action 2 (Index No. 655238/2026) against the Company, its former chief financial officer and directors, its independent auditor, and the IPO underwriters Dominari Securities LLC, Pacific Century Securities, LLC, and Revere Securities LLC.
• Both complaints assert claims under Sections 11 and 12(a)(2) of the Securities Act, and Section 15 claims against certain individual defendants. The proposed classes cover persons who acquired the Company’s securities in, or pursuant or traceable to, the offering documents for the Company’s Aug 2025 initial public offering. The complaints allege material misstatements and omissions concerning risks of stock-price manipulation and alleged deficiencies in underwriter due diligence, anti-money laundering compliance, supervision, and business-communication monitoring. Neither complaint asserts a fraud claim against the Company.

Key details

• Action 1 filed Jul 23, 2026 (Index No. 159271/2026); Action 2 filed Sep 14, 2026 (Index No. 655238/2026).
• Defendants include Curanex Pharmaceuticals Inc, underwriters Dominari Securities LLC, Pacific Century Securities, LLC, Revere Securities LLC, and additional issuers, underwriters, and individuals; Action 2 also names the former CFO, directors, and the independent auditor.
• Both complaints seek unspecified compensatory damages, interest, costs and expenses, rescission or rescissory damages, and equitable or other relief.
• Company’s deadline to respond to the Morales complaint was extended to Nov 15, 2026; plaintiff’s counsel agreed to extend the Company’s deadline to respond to the Lovett complaint through Dec 11, 2026.

Why it may matter

• Item reported: Item 8.01 (Other events) — legal proceedings. This item covers lawsuits and related claims filed against the Company and certain underwriters and individuals arising from the Company’s Aug 2025 IPO and the related registration statement and prospectuses. A filing does not show why the insider traded or why the company acted.